Charles Schwab Investment Management Inc Humanigen, Inc Transaction History

Charles Schwab Investment Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $116,644 - $220,695	-66,275 Reduced 20.14%	262,756 $466,000
Q1 2022 May 13, 2022	SELL	$1.81 - $3.97 $25,120 - $55,099	-13,879 Reduced 4.05%	329,031 $991,000
Q4 2021 Feb 11, 2022	BUY	$3.66 - $8.22 $91,474 - $205,442	24,993 Added 7.86%	342,910 $1.28 Million
Q3 2021 Nov 16, 2021	SELL	$5.93 - $17.83 $32,140 - $96,638	-5,420 Reduced 1.68%	317,917 $1.89 Million
Q2 2021 Aug 16, 2021	BUY	$13.54 - $22.74 $1.78 Million - $2.99 Million	131,426 Added 68.48%	323,337 $5.62 Million
Q1 2021 May 17, 2021	BUY	$12.91 - $23.83 $65,427 - $120,770	5,068 Added 2.71%	191,911 $3.67 Million
Q4 2020 Feb 16, 2021	BUY	$7.97 - $21.66 $1.49 Million - $4.05 Million	186,843 New	186,843 $3.27 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.